Eli Lilly’s shares up as oral GLP-1RA scores in first Phase III trial
Eli Lilly’s Phase III trial with its oral weight loss pill, orforglipron, has met its primary endpoint, reducing A1C levels…
Latest News
-
-
BMS’ Camzyos flops in Phase III non-obstructive hypertrophic cardiomyopathy trial
Bristol Myers Squibb’s (BMS) Phase III trial investigating Camzyos (mavacamten) in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) has failed to…
-
Pfizer drops obesity pill development after liver injury report
Pfizer has terminated the development of its oral obesity candidate danuglipron after a patient on a clinical trial with the…
-
UK Government to invest $764m into new health data service
The UK Government has announced a £600m ($764m) funding pot to create a new Health Data Research Service, reducing red…
-
Cassava ends simufilam Alzheimer’s programme after second Phase III failure
Cassava Sciences has officially stopped the development of its investigational drug simufilam in Alzheimer’s disease after it failed to show…
-
Roche’s discontinued Alzheimer’s drug shows signs of preventing onset
Roche’s discontinued Alzheimer’s disease drug has shown signs that it could prevent onset of the disease. The Phase II/III Knight…
-
J&J drops Phase III MDD programme due to lack of efficacy
Johnson & Johnson (J&J) is dropping its Phase III major depressive disorder (MDD) programme for aticaprant due to ‘insufficient efficacy…
-
Tris Pharma eyes approval after pain drug triumphs in second Phase III trial
Tris Pharma has reported another Phase III win with its investigational pain therapy, cebranopadol, and it is now setting up…
-
USAID: sponsors, agencies and foundations may have to fill funding gap
A shutdown of funding for the US Agency for International Development (USAID) could lead to the termination of clinical trials…
-
“Digital genocide”: BMJ post alleges patient data deletion amid DEI purge
The US government’s drive to eradicate wording relating to Diversity, Equity and Inclusion (DEI) as well as ‘gender ideology’ from…
